Study summary

An antibody-drug conjugate extended survival for recurrent cervical cancer

innovaTV 301 trial · 502 people, phase 3 · Published July 2024, New England Journal of Medicine; FDA full approval 2024

30%lower risk of death than chemotherapy

What was tested

Tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, against chemotherapy, for recurrent cervical cancer after one or two earlier treatments.

What they found

Median survival was 11.5 vs 9.5 months, a 30% lower risk of death.
Eye side effects require preventive eye drops and monitoring.

What it means

A standard option after first-line treatment for recurrent disease.

N Engl J Med, via PubMed ↗ ← Back to the outlook

Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.